Open access · Peer reviewed · Scopus journal
A new drug belonging to a novel class of drugs for type 2 diabetes
- 1*
- 1Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Sivagnanam G
Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India.
Email: drsivagnanam@gmail.com
Copyright: © 2013 The Author(s). This is an open access article.
Abstract
The FDA approval of canagliflozin (Invokana) was based on data involving over 10,285 type 2 diabetes patients, which showed improvement in hemoglobin A1c and fasting plasma glucose levels. Canagliflozin has been tested as monotherapy as well as in combination with metformin, sulphonylurea, pioglitazone, and insulin
Keywords
Subject
Recommended articles
- Antibiotics with a curse of cardiovascular risk
G Sivagnanam · Journal of Pharmacology and Pharmacotherapeutics
- Acetaminophen associated with risk of hearing loss: A safety alert
Sangeeta Bhanwra, Kaza Ahluwalia · Journal of Pharmacology and Pharmacotherapeutics
- New(s): Are these terms new(s)!?
G. Sivagnanam · Journal of Pharmacology and Pharmacotherapeutics
- Majority general practitioners prescribe “Impure Placebo” drugs
· Journal of Pharmacology and Pharmacotherapeutics
- The enema of your enemy is your friend
· Journal of Pharmacology and Pharmacotherapeutics
- C‑section, formula may disrupt ‘good’ gut bacteria in babies
Sivagnanam G · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026